**(**Stockholm januari 24, 2020) **Inhalation Sciences (ISAB) har tecknat ett kontraktsforskningsuppdrag (CRO) värt 750k SEK med en befintlig kund som även tidigare anlitat ISAB för  omfattande uppdrag samt  köpt ISABs labinstrument.**

Det totala värdet på beställningen uppgår till 1,1 MSEK, varav 750 KSEK är för ISAB’s förtjänster och resterande 350 KSEK till en samarbetspartner för bioanalys inom projektet. Uppdraget omfattar ISAB’s nya _in vitro_\-simuleringsverktyg Dissolv*It* och dess IPL-modul (Isolerad Perfuserad Lunga).

ISAB’s vd Manoush Masarrat ”När kunder av denna kaliber återkommer gång på gång är det ett bevis på att de värdesätter den data vi levererar och ger dem stora konkurrensfördelar”.

”För ISAB, kommer 2020 att bli ett spännande år då vi planerar lansera Dissolv*It* för kommersiellt bruk , och detta är en fantastisk start. Dissolv*It_s IVIVC (\_In Vitro In Vivo* Correlation) genererar kvalitativ data, i form av Cmax- och Tmax-kurvor, som hittills inte har kunnat påvisas  med konventionella _in vitro-_ och _in vivo_\- teknologier. I år ser vi att medvetenheten kring Dissolv*It* kommer att öka avsevärt som ett led i att   kommersiella laboratorier som genererar trovärdiga, repeterbara IVIVC-data. Detta är en utmärkt start på detta år!”

**För mer information om detta pressmeddelande, vänligen kontakta:**

Manoush Masarrat, VD

E-post: Manoush.masarrat@inhalation.se

Telefon: +46 (0)73 628 9153

**Om Inhalations Sciences Sweden AB (publ)**

Inhalation Sciences Sweden AB (publ) utvecklar och kommersialiserar världsledande instrument för forskning inom inhalation. Bolagets patenterade labinstrument, PreciseInhale® erbjuder forskare möjligheten att, med mycket hög precision, karakterisera hur aerosoler och små partiklar påverkar våra lungor och därmed vår hälsa när dessa inandas.

**Informationen ovan tillhandahölls av Inhalation Sciences AB enligt EU: s marknadsmissbruksförordningar. Informationen lämnades via ovanstående kontaktperson för offentliggörande den 24 januari 2020.**

![](https://res.cloudinary.com/ipo-se/image/upload/v1624359751/a7078a665fa5a3fd_f8e3d9af56.png)


Inhalation Sciences tecknar CRO-kontrakt värt 750 KSEK med globalt företag

**Fraunhofer ITEM (Institute for Toxicology and Experimental Medicine) is one of the world’s leading toxicology research organizations. At the SOT (Society of Toxicology) 2019 Conference in Baltimore it presented innovative research carried out using Inhalation Sciences’ PreciseInhale, to over 100 scientists at a packed exhibitor-hosted seminar.**

“It was an early seminar right at the beginning of the day—but it was packed” says ISAB CEO Lena Heffler. “The seminar presented PreciseInhale and highly innovative research into animal-free testing carried out using it. The general response was that this is high-status, high-quality work using a precise, fascinating methodology.”

**ANIMAL-FREE RESPIRATORY TESTING**

_“Animal-Free Testing Strategies for Risk Assessment of Inhalable compounds”,_ described in detail how Fraunhofer ITEM validate and explore toxicology research without using animals.

“They had chosen relevant tox substances for which they had _in vivo_ data” says Heffler “and showed various ways they could screen to produce convincing _in vitro_ data. Detailed data on the nerves, bronchial constriction, immunological cells and general toxicity in the whole epithelia was generated from very small samples of live lung tissue and other methodologies.”

**GROWING INTEREST IN ANIMAL-FREE TESTING IN THE US**

Replacing, reducing and refining the use of animals in medical testing—the 3Rs—is a well-recognized research priority in Europe. Less so in the US. But that could be changing. “We sensed growing interest,” Heffler says. CSO Per Gerde attended the session “Establishing Effective Alternatives for Acute Oral and Inhalation Systemic Toxicity Testing”. Here representatives from a number of companies, organisations and institutions spoke including Integrated Laboratory Systems ILS, Dow Chemicals and PETA (People for Ethical Treatment of Animals). There is a clear interest for alternative toxicity testing.

“For us as a strong _in vitro_ company with a novel one-animal-at-a-time methodology it was heartening to see.” says Heffler.

**LOW SUBSTANCE CONSUMPTION REMAINS POWERFUL DIFFERENTIATOR**

ISAB’s Product & Sales Manager Mikael Mikko was in charge of ISAB’s Stand at the event, meeting a wide range of attendees. “The fact that we can run whole tox’ studies, delivering detailed, voluminous data from just 100 mg or less of test substance—that remains a powerful differentiator for us” Mikko says. “In the States high-consumption tox testing requiring large groups of animals to be exposed for up to 28 days is still the norm for many. When we present exceptionally precise data generated from just one animal—in a short, _in vivo_ exposure using tiny amounts of test substance—every time that is of interest.”

SOT was Lena Heffler’s first major Toxicology event as ISAB CEO: “SOT is massive, with 315 exhibitors, 6,000 attendees and hundreds of Research Posters. Yet whatever booth I went into I was warmly welcomed. I had the strong sense that the market knows us now, knows we have something out of the ordinary and realizes we are here to stay. To them we signal quality and precision. Many companies were interested in pursuing a dialogue and partnering up with us.”

Mikael Mikko: “We generated 40 leads at the event and a lot of spontaneous meetings as well as the four pre-scheduled ones we had. ISAB Technology also appeared on a well-received Karolinska Institutet poster presented by Senior Staff Researcher in Toxicology Anna Steneholm. Events like these are crucial for us. And this one went well.”

**For more information on Inhalation Sciences, please contact** **Lena Heffler, CEO**

**E-mail:** lena.heffler@inhalation.se **Telephone:** +46 (0)70 205 9620

**About Inhalations Sciences Sweden AB (publ)**

**I**nhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company’s patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when we breathe them in.

![](https://res.cloudinary.com/ipo-se/image/upload/v1624359751/a7078a665fa5a3fd_f8e3d9af56.png)


Aerosol news

Inhalation Sciences tecknar CRO-kontrakt värt 750 KSEK med globalt företag

Inhalation Sciences' PreciseInhale center stage at packed Fraunhofer ITEM seminar, SOT 2019